Furthermore, our signature demonstrated superior predictive ability for the prognosis of NB patients compared to evaluating prognosis based on MYCN amplification alone, as evidenced by higher AUC values for 3-year and 5-year EFS (0.710 vs. 0.581; 0.698 vs. 0.576) and OS (0.813 vs. 0.581; 0.855 vs. 0.576), as shown in Figures 5C-F). This evidence concerns the gene MYCN and neuroblastoma.